CN117567453A - 作为布鲁顿氏酪氨酸激酶的抑制剂的苯并氮杂卓类似物 - Google Patents

作为布鲁顿氏酪氨酸激酶的抑制剂的苯并氮杂卓类似物 Download PDF

Info

Publication number
CN117567453A
CN117567453A CN202311088635.7A CN202311088635A CN117567453A CN 117567453 A CN117567453 A CN 117567453A CN 202311088635 A CN202311088635 A CN 202311088635A CN 117567453 A CN117567453 A CN 117567453A
Authority
CN
China
Prior art keywords
tert
butyl
benzo
tetrahydro
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311088635.7A
Other languages
English (en)
Chinese (zh)
Inventor
B·T·霍普金斯
B·马
R·普林斯
I·马克斯
J·P·莱西卡托斯
F·郑
M·彼得森
D·B·佩兴斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bojian Massachusetts Co ltd
Original Assignee
Bojian Massachusetts Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bojian Massachusetts Co ltd filed Critical Bojian Massachusetts Co ltd
Publication of CN117567453A publication Critical patent/CN117567453A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202311088635.7A 2017-04-14 2018-04-13 作为布鲁顿氏酪氨酸激酶的抑制剂的苯并氮杂卓类似物 Pending CN117567453A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762485745P 2017-04-14 2017-04-14
US62/485,745 2017-04-14
CN201880031744.6A CN110621670B (zh) 2017-04-14 2018-04-13 作为布鲁顿氏酪氨酸激酶的抑制剂的苯并氮杂卓类似物
PCT/US2018/027415 WO2018191577A1 (en) 2017-04-14 2018-04-13 Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880031744.6A Division CN110621670B (zh) 2017-04-14 2018-04-13 作为布鲁顿氏酪氨酸激酶的抑制剂的苯并氮杂卓类似物

Publications (1)

Publication Number Publication Date
CN117567453A true CN117567453A (zh) 2024-02-20

Family

ID=62092333

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311088635.7A Pending CN117567453A (zh) 2017-04-14 2018-04-13 作为布鲁顿氏酪氨酸激酶的抑制剂的苯并氮杂卓类似物
CN201880031744.6A Active CN110621670B (zh) 2017-04-14 2018-04-13 作为布鲁顿氏酪氨酸激酶的抑制剂的苯并氮杂卓类似物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880031744.6A Active CN110621670B (zh) 2017-04-14 2018-04-13 作为布鲁顿氏酪氨酸激酶的抑制剂的苯并氮杂卓类似物

Country Status (36)

Country Link
US (5) US10227341B2 (cg-RX-API-DMAC7.html)
EP (2) EP4249071A3 (cg-RX-API-DMAC7.html)
JP (3) JP7145874B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250140646A (cg-RX-API-DMAC7.html)
CN (2) CN117567453A (cg-RX-API-DMAC7.html)
AR (2) AR111594A1 (cg-RX-API-DMAC7.html)
AU (3) AU2018253209B2 (cg-RX-API-DMAC7.html)
CA (1) CA3058774A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002900A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019012571A2 (cg-RX-API-DMAC7.html)
CR (2) CR20190517A (cg-RX-API-DMAC7.html)
DK (1) DK3609886T3 (cg-RX-API-DMAC7.html)
EA (1) EA201992354A1 (cg-RX-API-DMAC7.html)
ES (1) ES2975769T3 (cg-RX-API-DMAC7.html)
FI (1) FI3609886T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240361T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066253T2 (cg-RX-API-DMAC7.html)
IL (3) IL269933B (cg-RX-API-DMAC7.html)
JO (1) JOP20190233B1 (cg-RX-API-DMAC7.html)
LT (1) LT3609886T (cg-RX-API-DMAC7.html)
MA (1) MA50013B1 (cg-RX-API-DMAC7.html)
MD (1) MD3609886T2 (cg-RX-API-DMAC7.html)
MX (1) MX2023000812A (cg-RX-API-DMAC7.html)
PE (2) PE20240930A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019502334A1 (cg-RX-API-DMAC7.html)
PL (1) PL3609886T3 (cg-RX-API-DMAC7.html)
PT (1) PT3609886T (cg-RX-API-DMAC7.html)
RS (1) RS65386B1 (cg-RX-API-DMAC7.html)
SA (1) SA519410292B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201909224QA (cg-RX-API-DMAC7.html)
SI (1) SI3609886T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400166T1 (cg-RX-API-DMAC7.html)
TW (2) TWI846229B (cg-RX-API-DMAC7.html)
UA (1) UA127347C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018191577A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202306172B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181109T1 (hr) 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
RS65386B1 (sr) 2017-04-14 2024-04-30 Biogen Ma Inc Benzoazepinski analozi kao sredstva za inhibiciju brutonove tirozin kinaze
US11820760B2 (en) 2018-10-15 2023-11-21 Biogen Ma Inc. Crystalline polymorphs of Bruton's tyrosine kinase inhibitors
JP7747523B2 (ja) * 2019-05-15 2025-10-01 バイオジェン・エムエイ・インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
US20240216330A1 (en) * 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2023086521A1 (en) 2021-11-10 2023-05-19 Biogen Ma Inc. Btk inhibitors
CA3240051A1 (en) 2021-12-30 2023-07-06 Beigene Switzerland Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160096834A1 (en) * 2014-10-06 2016-04-07 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
CN106459002A (zh) * 2013-12-11 2017-02-22 比奥根Ma公司 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
ES2406129T3 (es) 2007-10-05 2013-06-05 Verastem, Inc. Derivados de purina sustituidos con pirimidina
JPWO2009107391A1 (ja) 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI557127B (zh) * 2009-09-04 2016-11-11 百健Ma公司 布魯頓氏酪胺酸激酶抑制劑
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
CN103889987B (zh) 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
TWI648274B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 (二)
US20140357636A1 (en) 2013-02-21 2014-12-04 Wayne Rothbaum Treatment of Skeletal-Related Disorders
US10329270B2 (en) 2013-10-21 2019-06-25 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
RS65386B1 (sr) 2017-04-14 2024-04-30 Biogen Ma Inc Benzoazepinski analozi kao sredstva za inhibiciju brutonove tirozin kinaze

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459002A (zh) * 2013-12-11 2017-02-22 比奥根Ma公司 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物
US20160096834A1 (en) * 2014-10-06 2016-04-07 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof

Also Published As

Publication number Publication date
IL316713A (en) 2024-12-01
PE20240930A1 (es) 2024-04-30
EA201992354A1 (ru) 2020-03-10
CA3058774A1 (en) 2018-10-18
JP2022180498A (ja) 2022-12-06
CL2019002900A1 (es) 2020-01-24
US20180362522A1 (en) 2018-12-20
EP3609886B1 (en) 2024-02-07
US20210340135A1 (en) 2021-11-04
TW201841909A (zh) 2018-12-01
JOP20190233A1 (ar) 2019-10-02
JP2025020247A (ja) 2025-02-12
US11427577B2 (en) 2022-08-30
PT3609886T (pt) 2024-04-11
MD3609886T2 (ro) 2024-07-31
ZA202306172B (en) 2024-11-27
US10227341B2 (en) 2019-03-12
HUE066253T2 (hu) 2024-07-28
UA127347C2 (uk) 2023-07-26
CN110621670A (zh) 2019-12-27
PL3609886T3 (pl) 2024-05-13
KR20250140646A (ko) 2025-09-25
AR111594A1 (es) 2019-07-31
BR112019021399A2 (pt) 2020-04-28
JP2020516659A (ja) 2020-06-11
MX2023000812A (es) 2023-02-27
IL294175B2 (en) 2025-04-01
TWI846229B (zh) 2024-06-21
KR102862996B1 (ko) 2025-09-22
KR102607900B1 (ko) 2023-11-29
DK3609886T3 (da) 2024-03-18
SMT202400166T1 (it) 2024-07-09
AU2018253209B2 (en) 2022-06-02
KR20190139926A (ko) 2019-12-18
JP7778206B2 (ja) 2025-12-01
TW202315870A (zh) 2023-04-16
PH12019502334A1 (en) 2020-09-21
PE20200740A1 (es) 2020-07-24
AU2018253209A1 (en) 2019-10-31
TWI790227B (zh) 2023-01-21
IL269933A (cg-RX-API-DMAC7.html) 2019-11-28
CR20230539A (es) 2024-04-08
US10961237B2 (en) 2021-03-30
SI3609886T1 (sl) 2024-05-31
HRP20240361T1 (hr) 2024-06-07
IL294175A (en) 2022-08-01
JP7581294B2 (ja) 2024-11-12
IL269933B (en) 2022-07-01
SG11201909224QA (en) 2019-11-28
NZ757929A (en) 2025-10-31
MA50013A (fr) 2020-07-08
CR20190517A (es) 2020-02-13
IL294175B1 (en) 2024-12-01
LT3609886T (lt) 2024-04-10
JP7145874B2 (ja) 2022-10-03
US10189829B2 (en) 2019-01-29
JOP20190233B1 (ar) 2024-04-18
EP4249071A2 (en) 2023-09-27
US11858926B2 (en) 2024-01-02
AU2022218560A1 (en) 2022-09-15
RS65386B1 (sr) 2024-04-30
ES2975769T3 (es) 2024-07-15
CO2019012571A2 (es) 2020-01-17
EP4249071A3 (en) 2024-01-24
KR20230164247A (ko) 2023-12-01
AU2024204241A1 (en) 2024-07-11
SA519410292B1 (ar) 2023-03-12
EP3609886A1 (en) 2020-02-19
FI3609886T3 (fi) 2024-03-26
US20200239459A1 (en) 2020-07-30
CN110621670B (zh) 2023-09-15
WO2018191577A1 (en) 2018-10-18
AR129632A2 (es) 2024-09-11
AU2022218560B2 (en) 2024-04-04
MA50013B1 (fr) 2024-05-31
US20230147490A1 (en) 2023-05-11
US20180297992A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
JP7778206B2 (ja) ブルトン型チロシンキナーゼの阻害剤としてのベンゾアゼピン類似体
HK40100583A (en) Benzoazepine analogs as inhibiting agents for bruton’s tyrosine kinase
HK40022870B (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
HK40022870A (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
EA040817B1 (ru) Аналоги бензоазепина в качестве ингибирующих агентов для тирозинкиназы брутона
EA047837B1 (ru) Аналоги бензоазепина в качестве ингибирующих агентов для тирозинкиназы брутона
BR112019021399B1 (pt) Análogos de benzoazepina como agentes inibidores para tirosina quinase de bruton e seu uso, forma cristalina a e g e composição farmacêutica

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination